Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
Identifieur interne : 001658 ( Ncbi/Merge ); précédent : 001657; suivant : 001659Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
Auteurs : E. Lunell [Suède] ; L. Molander [Suède] ; M. Andersson [Suède]Source :
- European Journal of Clinical Pharmacology [ 0031-6970 ] ; 1995.
Abstract
The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state.
Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72.
The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.
Url:
DOI: 10.1007/BF00202176
PubMed: 7542589
PubMed Central: 7087527
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000252
- to stream Pmc, to step Curation: 000252
- to stream Pmc, to step Checkpoint: 000A50
Links to Exploration step
PMC:7087527Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title><author><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name><affiliation wicri:level="1"><nlm:aff id="Aff1">Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund</wicri:regionArea><wicri:noRegion>S-222 20 Lund</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Clinical Pharmacology,</institution><institution>University Hospital,</institution></institution-wrap>Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Lund</wicri:regionArea></affiliation></author><author><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name><affiliation wicri:level="1"><nlm:aff id="Aff1">Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund</wicri:regionArea><wicri:noRegion>S-222 20 Lund</wicri:noRegion></affiliation></author><author><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name><affiliation wicri:level="1"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Oto-rhino-laryngology,</institution><institution>University Hospital,</institution></institution-wrap>Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Lund</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">7542589</idno><idno type="pmc">7087527</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087527</idno><idno type="RBID">PMC:7087527</idno><idno type="doi">10.1007/BF00202176</idno><date when="1995">1995</date><idno type="wicri:Area/Pmc/Corpus">000252</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000252</idno><idno type="wicri:Area/Pmc/Curation">000252</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000252</idno><idno type="wicri:Area/Pmc/Checkpoint">000A50</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A50</idno><idno type="wicri:Area/Ncbi/Merge">001658</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title><author><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name><affiliation wicri:level="1"><nlm:aff id="Aff1">Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund</wicri:regionArea><wicri:noRegion>S-222 20 Lund</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Clinical Pharmacology,</institution><institution>University Hospital,</institution></institution-wrap>Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Lund</wicri:regionArea></affiliation></author><author><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name><affiliation wicri:level="1"><nlm:aff id="Aff1">Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund</wicri:regionArea><wicri:noRegion>S-222 20 Lund</wicri:noRegion></affiliation></author><author><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name><affiliation wicri:level="1"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Oto-rhino-laryngology,</institution><institution>University Hospital,</institution></institution-wrap>Lund, Sweden</nlm:aff><country xml:lang="fr">Suède</country><wicri:regionArea>Lund</wicri:regionArea></affiliation></author></analytic><series><title level="j">European Journal of Clinical Pharmacology</title><idno type="ISSN">0031-6970</idno><idno type="eISSN">1432-1041</idno><imprint><date when="1995">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state.</p><p>Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of C<sub>max</sub>, AUC and t<sub>max</sub> were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the t<sub>max</sub> ratio to 1.72.</p><p>The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Pontiroli, Ae" uniqKey="Pontiroli A">AE Pontiroli</name></author><author><name sortKey="Calderara, A" uniqKey="Calderara A">A Calderara</name></author><author><name sortKey="Pozza, G" uniqKey="Pozza G">G Pozza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russel, Mah" uniqKey="Russel M">MAH Russel</name></author><author><name sortKey="Jarvis, Mj" uniqKey="Jarvis M">MJ Jarvis</name></author><author><name sortKey="Feyerabend, C" uniqKey="Feyerabend C">C Feyerabend</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russel, Mah" uniqKey="Russel M">MAH Russel</name></author><author><name sortKey="Jarvis, Mj" uniqKey="Jarvis M">MJ Jarvis</name></author><author><name sortKey="Feyerabend, C" uniqKey="Feyerabend C">C Feyerabend</name></author><author><name sortKey="Ferno, O" uniqKey="Ferno O">O Fernö</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jarvis, Mj" uniqKey="Jarvis M">MJ Jarvis</name></author><author><name sortKey="Hajek, P" uniqKey="Hajek P">P Hajek</name></author><author><name sortKey="Russel, Mah" uniqKey="Russel M">MAH Russel</name></author><author><name sortKey="West, Rj" uniqKey="West R">RJ West</name></author><author><name sortKey="Feyerabend, C" uniqKey="Feyerabend C">C Feyerabend</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schneider, Ng" uniqKey="Schneider N">NG Schneider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jackson, Gg" uniqKey="Jackson G">GG Jackson</name></author><author><name sortKey="Dowling, Hf" uniqKey="Dowling H">HF Dowling</name></author><author><name sortKey="Spiesman, Ig" uniqKey="Spiesman I">IG Spiesman</name></author><author><name sortKey="Boand, Av" uniqKey="Boand A">AV Boand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olsson, P" uniqKey="Olsson P">P Olsson</name></author><author><name sortKey="Kuylenstierna, F" uniqKey="Kuylenstierna F">F Kuylenstierna</name></author><author><name sortKey="Johansson, C J" uniqKey="Johansson C">C-J Johansson</name></author><author><name sortKey="Gunnar, Po" uniqKey="Gunnar P">PO Gunnar</name></author><author><name sortKey="Bende, M" uniqKey="Bende M">M Bende</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sutherland, G" uniqKey="Sutherland G">G Sutherland</name></author><author><name sortKey="Stapleton, Ja" uniqKey="Stapleton J">JA Stapleton</name></author><author><name sortKey="Russell, Mah" uniqKey="Russell M">MAH Russell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hjalmarsson, A" uniqKey="Hjalmarsson A">A Hjalmarsson</name></author><author><name sortKey="Franzon, M" uniqKey="Franzon M">M Franzon</name></author><author><name sortKey="Westin, " uniqKey="Westin ">Å Westin</name></author><author><name sortKey="Wiklund, O" uniqKey="Wiklund O">O Wiklund</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greiff, L" uniqKey="Greiff L">L Greiff</name></author><author><name sortKey="Wollmer, P" uniqKey="Wollmer P">P Wollmer</name></author><author><name sortKey="Svensson, C" uniqKey="Svensson C">C Svensson</name></author><author><name sortKey="Andersson, M" uniqKey="Andersson M">M Andersson</name></author><author><name sortKey="Persson, Cga" uniqKey="Persson C">CGA Persson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greiff, L" uniqKey="Greiff L">L Greiff</name></author><author><name sortKey="Svensson, C" uniqKey="Svensson C">C Svensson</name></author><author><name sortKey="Andersson, M" uniqKey="Andersson M">M Andersson</name></author><author><name sortKey=" Kerlund, A" uniqKey=" Kerlund A">A Åkerlund</name></author><author><name sortKey="Wollmer, P" uniqKey="Wollmer P">P Wollmer</name></author><author><name sortKey="Alkner, U" uniqKey="Alkner U">U Alkner</name></author><author><name sortKey="Persson, Cga" uniqKey="Persson C">CGA Persson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Persson, Cga" uniqKey="Persson C">CGA Persson</name></author><author><name sortKey="Erjef Lt, I" uniqKey="Erjef Lt I">I Erjefält</name></author><author><name sortKey="Alkner, U" uniqKey="Alkner U">U Alkner</name></author><author><name sortKey="Baumgarten, C" uniqKey="Baumgarten C">C Baumgarten</name></author><author><name sortKey="Greiff, L" uniqKey="Greiff L">L Greiff</name></author><author><name sortKey="Gustafsson, B" uniqKey="Gustafsson B">B Gustafsson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bende, M" uniqKey="Bende M">M Bende</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Russell, Mah" uniqKey="Russell M">MAH Russell</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Clin. Pharmacol</journal-id><journal-title-group><journal-title>European Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0031-6970</issn><issn pub-type="epub">1432-1041</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">7542589</article-id><article-id pub-id-type="pmc">7087527</article-id><article-id pub-id-type="publisher-id">BF00202176</article-id><article-id pub-id-type="doi">10.1007/BF00202176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacoepidemiology and Disposition</subject></subj-group></article-categories><title-group><article-title>Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lunell</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Molander</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Andersson</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20 Lund, Sweden</aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Clinical Pharmacology,</institution><institution>University Hospital,</institution></institution-wrap>Lund, Sweden</aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Department of Oto-rhino-laryngology,</institution><institution>University Hospital,</institution></institution-wrap>Lund, Sweden</aff></contrib-group><pub-date pub-type="ppub"><year>1995</year></pub-date><volume>48</volume><issue>1</issue><fpage>71</fpage><lpage>75</lpage><history><date date-type="received"><day>20</day><month>5</month><year>1994</year></date><date date-type="accepted"><day>21</day><month>10</month><year>1994</year></date></history><permissions><copyright-statement>© Springer-Verlag 1995</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p>The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state.</p><p>Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of C<sub>max</sub>, AUC and t<sub>max</sub> were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the t<sub>max</sub> ratio to 1.72.</p><p>The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</p></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>Nicotine</kwd><kwd>Rhinitis</kwd><kwd>pharmacokinetics</kwd><kwd>nasal spray</kwd><kwd>xylometazoline</kwd><kwd>drug interaction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag 1995</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc><affiliations><list><country><li>Suède</li></country></list><tree><country name="Suède"><noRegion><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name></noRegion><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001658 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001658 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:7087527
|texte= Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:7542589" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |